LILRB1 and neoplasm: Regarding the suggested interplay between the two axes CD47:SIRPα and HLA class I:LILRB1 in counteracting effective ADCP of tumor cells as demonstrated for anti-EpCAM or anti-EGFR antibodies (19), additional antibody combinations were studied.